Clinical Research Directory
Browse clinical research sites, groups, and studies.
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Sponsor: Fudan University
Summary
Despite the impressive response rate to third-generation EGFR-TKIs, resistance inevitably develops in most patients. Stereotactic radiotherapy plays a growing role in the management of patients with brain metastasis. This study aims to evaluate the efficacy and safety of stereotactic radiotherapy for oligo-residual intracranial disease after first-line third-generation EGFR Inhibitors.
Official title: Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Oligo-residual Intracranial Disease After First-line Third-generation EGFR Inhibitors: a Multicenter, Randomized Clinical Trial.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
202
Start Date
2023-08-10
Completion Date
2028-08-10
Last Updated
2025-09-15
Healthy Volunteers
No
Interventions
EGFR-TK Inhibitor
Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
Stereotactic radiotherapy
Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China